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Abstract
Liver fibrosis is a major cause of liver failure, but treatment remains ineffective. In the present study, we investigated the
mechanisms and anti-hepatofibrotic activities of asiatic acid (AA) in a rat model of liver fibrosis induced by carbon
tetrachloride (CCl4) and in vitro in TGF-beta1-stimulated rat hepatic stellate cell line (HSC-T6). Treatment with AA
significantly attenuated CCl4-induced liver fibrosis and functional impairment in a dosage-dependent manner, including
blockade of the activation of HSC as determined by inhibiting de novo alpha smooth muscle actin (a-SMA) and collagen
matrix expression, and an increase in ALT and AST (all p,0.01). The hepatoprotective effects of AA on fibrosis were
associated with upregulation of hepatic Smad7, an inhibitor of TGF-beta signaling, thereby blocking upregulation of TGF-
beta1 and CTGF and the activation of TGF-beta/Smad signaling. The anti-fibrosis activity and mechanisms of AA were
further detected in vitro in HSC-T6. Addition of AA significantly induced Smad7 expression by HSC-T6 cells, thereby
inhibiting TGF-beta1-induced Smad2/3 activation, myofibroblast transformation, and collagen matrix expression in a
dosage-dependent manner. In contrast, knockdown of Smad7 in HSC-T6 cells prevented AA-induced inhibition of HSC-T6
cell activation and fibrosis in response to TGF-beta1, revealing an essential role for Smad7 in AA-induced anti-fibrotic
activities during liver fibrosis in vivo and in vitro. In conclusion, AA may be a novel therapeutic agent for liver fibrosis.
Induction of Smad7-dependent inhibition of TGF-beta/Smad-mediated fibrogenesis may be a central mechanism by which
AA protects liver from injury.
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Introduction
Liver fibrosis represents the final common pathway of virtually
all chronic liver diseases. It is characterized by the excessive
accumulation of extracellular matrix (ECM) and activated hepatic
stellate cells (HSC) that are undergoing myofibroblast transition
identified by de novo a-SMA expression [1,2]. Although a
significant progress has been made in our understanding of
hepatic fibrosis, treatment for liver fibrosis remains ineffective.
Therefore, there is an urgent need for searching and developing
antifibrotic strategies which can prevent, halt or reverse hepatic
fibrosis.
In hepatic fibrosis, the excessive ECM, including collagen type I
and III, is produced by activated mesenchymal cells which
resemble myofibroblasts derived from quiescent HSC, periportal
or perivenular fibroblasts, circulating fibrocytes, and bone marrow
cells [1,2]. Increasing evidence shows that TGF-beta1 is a key
mediator in the process of liver fibrosis [3,4]. The finding of
increased HSCl activation and liver fibrosis in mice with
tetracycline-regulated TGF-beta1 expression in the liver provides
a direct evidence for a critical role of TGF-beta1 in hepatic fibrosis
[5]. It is now clear that after binding to its receptors, TGF-beta1
activates its downstream signaling pathway, Smad 2 and Smad3,
to mediate fibrosis, which is negatively regulated by Smad7, an
inhibitor of TGF-beta signaling, via the ubiquitin-proteasome
degradation mechanism [6,7]. In the context of liver fibrosis,
Smad3 is pathogenic because mice null for Smad3 are protected
against dimethylnitrosamine-induced hepatic fibrosis [8]. In
contrast, Smad7 is protective since deletion of Smad7 promotes,
but overexpression of Smad7 protects against HSC activation and
hepatic fibrosis in vitro and in vivo [9–11]. The inhibitory role of
Smad7 in fibrosis is also found in chronic kidney disease [12]. We
detected that disruption of Smad7 gene promotes renal fibrosis in
a mouse model of obstructive nephropathy [13]. In contrast,
overexpression of Smad7 is capable of inhibiting TGF-beta1 and
angiotensin II-induced fibrosis in vitro [14,15] and in a number of
disease models including diabetic nephropathy [16–18]. However,
it is also known that TGF-beta1 is an anti-inflammatory cytokine.
Thus, therapies with general blockade of TGF-beta1 may risk in
enhancing the inflammatory response, which has largely limited
the development of anti-TGF-beta therapy clinically. Nevertheless,
the better understanding of the mechanisms of TGF-beta/Smad
signaling in diseases associated with fibrosis may be a critical step
towards the development of novel and specific anti-fibrosis drugs.
Asiatic acid (AA) is one of the triterpenoid components found in
Centella asiatica [19]. Many studies have shown that AA has a variety
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31350of pharmacological effects on anti-inflammation [20,21], antioxida-
tion [22], anti-tumor [23,24], neuroprotection [25,26], and wound
healing [27,28]. In particular, AA has been shown to be a
hepatoprotective agent. A number of studies demonstrated that AA
can protect liver from injury via mechanisms underlying anti-
mitochondrial stress and cellular antioxidant system in cultured
hepatocytes and Kupffer cells, and in a mouse model induced by D-
galactosamine and lipopolysaccharides [29–31]. It has been also
reported that AAis capable ofinhibitingcollagen matrixproduction
by HSC and keloid fibroblasts by blocking the autocrine effect of
TGF-beta1 in vitro [32,33], however, the role and mechanisms by
which AA inhibits liver fibrosis remain largely unknown. Therefore,
the present study investigated the therapeutic effect and mecha-
nisms of AA in a rat model of CCl4-induced liver fibrosis and in vitro
in TGF-beta1-stimulated rat HSC-T6 cell line.
Methods
Asiatic Acid
Purified nature product of AA (95%) was obtained from
Changzhou Natural Product Inc (Guangxi, China) and was used
for in vivo treatment as described below, while the HPLC-purified
AA (Sigma-Aldrich, St. Louis, MO) was used for in vitro studies.
Animal Model of CCl4-Induced Liver Fibrosis and Asiatic
Acid Treatment
Male Sprague-Dawley (SD) rats (6–8 weeks of age, 180–200 g)
were obtained from the Guangdong Medical Laboratory Animal
Center, fed with a standard laboratory diet and tap water in a
temperature- and humidity-controlled animal house under 12-h
light–dark cycles. Forty rats were divided randomly into five
groups (n=8 for each group) including: 1) normal control, 2)
disease control, and 3) three AA treatment groups at doses of
0.5 mg/kg, 2 mg/kg, and 8 mg/kg, respectively. In addition, one
group of normal 6 rats was treated with a dose of 8 mg/kg of AA
as AA toxicity control. Except the normal control groups, all
animals were treated with intra-peritoneal injection of 2 ml/kg of
CCl4 (diluted in 20% peanut oil) twice per week for 6 weeks to
induce liver fibrosis. For those received the AA treatment, animals
were given with three different doses of AA (0.5, 2, and 8 mg/kg)
suspended in a 1.5% methyl cellulose (MC) mixture by oral gavage
daily for the 6 week-period, while rats from disease control group
Figure 1. AA treatment attenuates CCl4-induced liver damage and functional impairment in a dosage-dependent manner in rats.
A. Histology (H&E). B. Liver function. Data represent mean 6 SEM for groups of 8 animals. **p,0.01, *** p,0.001 versus normal control;
#p,0.05,
##p,0.01,
###p,0.001 versus CCl4-induced disease control. Magnification: 6100.
doi:10.1371/journal.pone.0031350.g001
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without AA. Normal control animals were also received the same
volumes of peanut oil equivalent to the CCl4-treated animals. To
exclude the toxicity of AA in vivo, one group of normal 6 rats was
treated with a dose of 8 mg/kg of AA following the same
experimental protocol of AA treatment. At the end of the sixth
Figure 2. Immunohistochemistry detects that AA treatment attenuates CCl4-induced liver fibrosis in a dosage-dependent manner
in rats. A. Collagen I expression. B. Collagen III expression. Data represent mean 6 SEM for groups of 8 animals. **p,0.01, *** p,0.001 versus
normal control;
##p,0.01,
###p,0.001 versus CCl4-induced disease control. Magnification: 6100.
doi:10.1371/journal.pone.0031350.g002
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pentobarbital (45 mg/kg, ip). Blood samples and liver specimens
were obtained for analyses of liver functions, mRNA and protein
expression of fibrotic indexes by real-time reverse transcription
polymerase chain reaction (RT-PCR), Western blot, histology, and
immunohistochemistry. All experimental procedures were ap-
proved by the Animal Experimental Committee at the First
People’s Hospital of Foshan (A0331).
Liver Function Test
Serum alanine transaminase (ALT) and aspartate transaminase
(AST) activities, markers for hepatotoxicity, were detected with an
automatic analyzer (Olympus, Japan) at the Department of
Chemical Pathology.
Histopathology and Immunohistochemistry
Changes in liver morphology were examined in methyl
Carnoy’s fixed, paraffin-embedded tissue sections (3 micrometer)
stained with hematoxylin and eosin. The histopathological scores
of fibrosis were evaluated following the published criteria [34]: 0)
normal liver; 1) an increase in collagen matrix accumulation
without the formation of septa (small stellate expansions of the
portal fields); 2) formation of incomplete septa from the portal tract
to the central vein (septa that do not interconnect with each other);
Figure 3. Immunohistochemistry detects that AA treatment attenuates CCl4-induced activation of HSC in a dosage-dependent
manner in rats. Activation of HSC was determined by a-SMA+ myofibroblast transition. A. Representative picture from a control rat treated with
20% peanut oil. B. Representative picture from a rat treated with CCl4. C–E. Representative pictures from CCl4-treated rats received AA in a dosage-
dependent manner. F. Quantitation of a-SMA+ cells. Data represent mean 6 SEM for groups of 8 animals. *** p,0.001 versus normal control;
##p,0.01,
###p,0.001 versus CCl4-induced disease rats. Magnification: 6200.
doi:10.1371/journal.pone.0031350.g003
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divide the parenchyma into separate fragments; 4) same as grade
3, except for the presence of thick septa (complete cirrhosis).
Immunohistochemistry was performed in paraffin sections using
the microwaved-based antigen retrieval method as described
previously [35]. Antibodies used in this study included: rabbit
polyclonal antibodies to collagen I, III (Southern Tech, Birming-
ham, AL), and a-SMA (Sigma, St. Louis, MO). An irrelevant
isotype rabbit IgG was used as a negative control. The stained
sections were developed with diaminobenzidine to produce brown
products and counterstained with hematoxylin.
Quantitation of immunostaining was carried out on coded slides
as previously described [13,18]. Expression of collagen I, III, and
a-SMA in the liver cross-sections was determined using the
quantitative Image Analysis System (AxioVision 4, Carl Zeiss,
Jena, Germany). Briefly, 10 fields (620) were randomly selected
from each section and positive signals within the section were
highlighted, measured, and expressed as percent positive area of
the entire liver tissues examined.
Cell culture
The HSC-T6 cell line was gifted by Professor SL Friedman
(Liver Disease Research Center of San Francisco General
Hospital, CA, USA). HSC-T6 cells were routinely cultured in
DMEM (Gibco, USA) supplemented with 10% heat-inactivated
fetal bovine serum (FBS).
Figure 4. Real-time PCR and Western blot analysis show that AA treatment blocks CCl4-induced liver fibrosis in a dosage-
dependent manner in rats. A. Real-time PCR for a-SMA, collagen type I and III mRNA expression. B. Western blot analysis for a-SMA, collagen type
I and III protein expression. Data represent mean 6 SEM for groups of 8 animals. *p,0.05, **p,0.01, *** p,0.001 versus normal control;
#p,0.05,
###p,0.001 versus CCl4-induced disease control.
doi:10.1371/journal.pone.0031350.g004
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T6 cells were cultured at a density of 5610
4 cells/mL in 100 uL
DMEM containing 0.2% FBS in 96-well microplates and AA or
DMSO as control in various dosages (0.0, 2.5, 5.0, 10.0, 20.0,
30.0, 40.0, 60.0, and 80.0 micro molar) was added to the culture
for 24 h. A dosage-dependent cytotoxicity of AA was measured by
3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide
(MTT) assay kit (Sigma-Aldrich) and lactate dehydrogenase (LDH)
release kit (Sigma-Aldrich) following the manufacturer instruc-
tions. The extent of cytotoxicity and the IC50 of AA were
calculated using the results of both MTT and LDH assays.
To determine the optimal dose of TGF-beta1 on collagen
matrix expression, HSC-T6 cells were treated with TGF-beta1
(R&D System) at dosages of 0.0, 0.1, 0.5, 1.0, 2.0, and 5.0 ng/ml
for various time of 0, 1, 3, 6, 12, 24 h. TGF-beta1-induced
collagen I and III expression was determined at the mRNA level
by real-time PCR and at the protein level by Western blot analysis.
To investigate the inhibitory effect and mechanism of AA on
TGF-beta1-mediated fibrosis, HSC-T6 cells were pre-treated with
AA at dosages of 0, 5, 10, 20, 30 micro molar for over night,
followed by addition of an optimal dose of TGF-beta1 (1 ng/ml)
for various time periods for examination of phospho-Smad2/3 and
expression of Smad7, collagen I, and a-SMA by real-time and
Western blot analysis as described below.
To confirm the protective role of AA in TGF-beta1-induced
fibrosis in HSC-T6 cells via induction of Smad7, a stable HSC-T6
cell line with Smad7 knockdown was established. In brief, Smad7
siRNA was cloned into the P-super1 plasmid and transfected into
HSC-T6 cells with lipofectamine 2000 following the manufactur-
er’s protocol (Invitrogen). The cells were then selected with G418
Figure 5. TGF-beta1 induces collagen I and a-SMA expression by HSC-T6 cells in vitro.A .Real-time PCR show that TGF-beta1 (1 ng/ml)
induces collagen I and a-SMA mRNA expression in a time and dosage-dependent manner. B. Western blot analysis for a time (TGF-beta1 1 ng/ml)
and dosage (24 h)-dependent effects of TGF-beta1 on collagen I expression. Data represent mean 6 SEM for at least 3 independent experiments.
*p,0.05, **p,0.01, ***p,0.001 versus medium control.
doi:10.1371/journal.pone.0031350.g005
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PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e31350Figure 6. AA inhibits TGF-beta1-induced collagen I and a-SMA expression by HSC-T6 cells in a dosage-dependent manner in vitro.
A. Dose-dependent effects of AA on cytotoxicity of HSC-T6 cells by MTT and LDH release assays. B and C. Real-time PCR and Western blot analysis
for a dosage-dependent inhibitory effect of AA on collagen type I and a-SMA expression. Data represent mean 6 SEM for at least 3 independent
experiments. *p,0.05, **p,0.01, ***p,0.001 versus medium control;
#p,0.05,
##p,0.01,
###p,0.001 versus TGF-beta1-treated, isotype control
antibody-treated (CTL Ab), or DMSO-treated cells.
doi:10.1371/journal.pone.0031350.g006
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PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e31350Figure 7. AA treatment upregulates hepatic Smad7, but blocks expression of TGF-beta1 and CTGF and activation of Smad2/3 in CCl4-
induced liver disease in rats. A. Real-time PCR analysis of TGF-beta1, CTGF, and Smad7 mRNA expression. B. Western blot analysis for levels of phospho-
Smad2/3 and Smad7 protein expression. C. Immunohistochemistry for nuclear location of phospho-Smad2/3. Data represent mean 6 SEM for groups of 8
animals.*p,0.05,**p,0.01,***p,0.001versusnormalcontrol;
#p,0.05,
##p,0.01,
###p,0.001versusCCl4-induceddiseasecontrol.Magnification:6200(C).
doi:10.1371/journal.pone.0031350.g007
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G418. A stable HSC-T6 cell line transfected with P-super1 empty
plasmid only was used as control.
Real-time Reverse Transcription Polymerase Chain
Reaction (RT-PCR)
Total RNA was extracted from frozen liver samples or cultured
cells using the RNeasy Mini Kit (Qiagen Inc)following the
manufacturer’s protocol. mRNA expression of collagen I, collagen
III, a-SMA, TGF-beta1, CTGF, Smad7, and GAPDH was
detected by quantitative real time PCR using an Opticon 2
DNA Engine Real Time PCR Detection (MJ Research Inc.,
Waltham, MA) as previously described [13,16,17]. The expression
levels of all the transcripts were normalized to that of the
housekeeping gene GAPDH in the same tissue.
Western Blot Analysis
Proteins extracted from either liver tissues or cultured HSC
were analyzed by Western blotting as previously described
[13,16,17]. Antibodies used in this study included: collagen I,
collagen III (Southern Biotech), a-SMA(Sigma, St. Louis, MO),
Smad7, phospho-Smad2/3 (Santa Cruz Biotechnology Inc., Santa
Cruz, CA), GAPDH (Chemicon Inc., Temecula, CA), and
IRDyeTM800 conjugated secondary antibodies (Rockland Im-
munochemical Inc., Gilbertsville, PA). Signals were scanned and
visualized by Odyssey Infrared Imaging System (LiCor Inc.,
Lincoln, NE). The ratio of the protein interested was subjected to
GAPDH and was densitometrically analyzed by Image J software
(NIH, Bethsda, MD).
Statistical Analyses
All data are expressed as mean 6 SEM. The differences
between multiple groups were evaluated by a one-way analysis of
variances (ANOVA), followed by Newman-Keuls Post Test using
Prism 4.0 Program (GraphPad Software, Inc. San Diego, CA).
Results
Asiatic Acid Treatment Inhibits CCl4-Induced Liver
Functional and Histological Damage
Administration of CCl4 for 6 weeks caused a moderate to severe
liver injury as demonstrated by the development of severe liver
damage with thick fibrotic septa and pseudolobular formation
(Fig. 1Aii, vi). Serologically, levels of ALT and AST were also
highly significantly elevated in disease control rats when compared
to normal control rats (Fig. 1B). In contrast, treatment with AA
resulted in attenuation of both histological and functional injury in
a dosage-dependent manner, being significant at doses of 2 and
8 mg/kg (Fig. 1A iii–vi and B). Normal rats treated with AA
(8 mg/kg) exhibited normal histological and serological changes
similar to the normal control rats (data not shown).
Asiatic Acid Treatment Attenuates CCl4-Induced Liver
Fibrosis in vivo
We next examined the therapeutic effect of AA on liver fibrosis.
As shown in Figure 2 , immunohistochemistry detected that
compared to normal control rats, CCl4-treatment caused a
remarkable collagen I and III accumulation in the liver (Fig. 2A
and B, i–ii). In contrast, treatment with AA reduced hepatic
collagen matrix accumulation in a dosage-dependent manner
(Fig. 2 A and B, iii–v), which was confirmed by quantitative
analysis (Fig. 2A and B, vi). Importantly, treatment with AA on
protection of liver from CCl4-induced fibrosis was associated with
Figure 8. AA blocks TGF-beta1-induced phosphorylation of
Smad2/3, a-SMA, and collagen matrix production by HSC-T6
cells in vitro. Western blot analysis detects that HSC-T6 cells pretreated
with AA (20 uM) for overnight blocks TGF-beta1 (1 ng/ml)-induced
Smad2/3 phosphorylation at 30 mins (A) and upregulation of a-SMA
and collagen I expression at 24 h (B,C). Data represent mean 6 SEM for
at least 3 independent experiments. **p,0.01, ***p,0.001 versus
medium control;
#p,0.05,
##p,0.01 versus TGF-beta1-treated or
DMSO-treated cells.
doi:10.1371/journal.pone.0031350.g008
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SMA+ myofibroblast transition. As shown in Figure 3, addition of
AA was capable of blocking a-SMA+ cell accumulation along the
fibrotic septa in a dosage-dependent manner.
The inhibitory effect of AA on liver fibrosis was also
demonstrated by at the mRNA levels by real-time PCR. As
shown in Figure 4(A), CCl4-induced upregulation of a-SMA and
collagen type I and III mRNA was significantly attenuated in those
treated with AA in a dose-dependent manner. These findings were
also evidenced by Western blot analysis (Fig. 4B).
Asiatic Acid Inhibits TGF-beta1-Induced HSC Activation
of Collagen Matrix Expression by HSC-T6 Cells in Vitro
Because TGF-beta1 has been long considered as a key mediator
in the pathogenesis of liver fibrosis [1–4], we examined if AA is
able to inhibit the fibrotic effects of TGF-beta1 on ECM
expression in a well-characterized HSC-T6 cells. We first
determined an optimal dose of TGF-beta1 in fibrosis response
on HSC-T6 cells. As shown in Figure 5, both real-time PCR and
Western blot analyses detected that addition of TGF-beta1
induced collagen I and a-SMA mRNA and protein expression in
a time- and dosage-dependent manner, being an optimal dose of
TGF-beta1 at 1 ng/ml with the peaked time for mRNA
expression at 6 h and protein expression at 24 h.
We then determined the safe dose of AA without causing
cytotoxicity for the in vitro study in HCS-T6 cells. As shown in
Figure 6(A), AA at doses over 40 micro molar (uM) caused a
significant cytotoxicity on HSC-T6 by inhibiting HSC-T6 cell
proliferation (MTT assay) and increasing LDH release. In
contrast, there was not detectable cytotoxicity when doses of AA
Figure 9. AA induces Smad7 expression by HSC-T6 cells in a time and dosage-dependent manner in vitro.A .Real-time PCR. B. Western
blots. Results show that addition of AA induces Smad7 mRNA and protein expression in a time (at a dose of 20 uM) and dosage (3 h for mRNA and
24 h for protein)-dependent manner. Data represent mean 6 SEM for at least 3 independent experiments. *p,0.05, **p,0.01, ***p,0.001 versus
medium control.
doi:10.1371/journal.pone.0031350.g009
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30 uM) were used for studying the inhibitory effect of AA on TGF-
beta1 (1 ng/ml)-induced HSC activation and ECM production in
vitro. As shown in Figure 6(B,C), real-time PCR demonstrated that
addition of AA significantly inhibited TGF-beta1-inudced collagen
I and a-SMA mRNA expression in a dosage-dependent manner,
being an optimal dose at 20-30 uM (Fig. 6B). Similar results were
also observed at the protein levels as demonstrated by Western
blot analysis (Fig. 6C).
Upregulation of Hepatic Smad7, thereby inhibiting TGF-
beta/Smad signaling, Is a Key Mechanism by Which
Asiatic Acid Attenuates hepatic fibrosis in vivo and
in vitro
Since TGF-beta/Smad signaling is a key pathway leading to
liver fibrosis [8–11], we then investigated the mechanisms by
which AA attenuates CCl4-induced liver fibrosis by examining the
TGF-beta/Smad signaling pathway. As shown in Figure 7,
compared to normal control rats, CCl4-induced liver fibrosis was
associated with a marked upregulation of TGF-beta1 and CTGF
mRNA (Fig. 7A), which was associated with a marked activation of
Smad2/3 as identified by higher levels of phospho-Smad2/3 and
its nuclear translocation (Fig.7B,C), and a fall of hepatic Smad7
(Fig. 7A and B). In contrast, diseased rats treated with AA
significantly reduced TGF-beta and CTGF mRNA expression and
blocked activation of Smad2/3 in a dosage-dependent manner
(Fig. 7). Importantly, the inhibitory effect of AA on TGF-beta/
Smad signaling was associated with a marked upregulation of
hepatic Smad7 as demonstrated at the mRNA level by real-time
PCR and at the protein level by Western blot analysis (Fig. 7 A
and B).
The mechanism of AA-induced upregulation of hepatic Smad7
to inhibit CCl4-induced liver fibrosis was further investigated in
vitro by knocking down Smad7 in HSC-T6 cells. Western blot
analysis detected that addition of AA, but not DMSO, was capable
of blocking TGF-beta1-induced phosphorylation of Smad2/3 and
a-SMA and collagen I expression by HSC-T6 cells (Fig.8). The
inhibitory effect of AA in TGF-beta/Smad-mediated hepatic
fibrosis was associated with upregulation of Smad7 as demon-
strated by the findings that AA alone was able to induce Smad7
mRNA and protein in a time and dosage-dependent manner
(Fig. 9 A and B). To further examine the hypothesis that AA
induces Smad7 to inhibit TGF-beta1-mediated hepatic fibrosis,
Smad7 gene was knocked down from HSC-T6 cells by siRNA
technique. As shown in Figure 10, knockdown of Smad7 from
HSC-T6 cells was able to prevent the inhibitory effect of AA on
TGF-beta1-induced collagen I and a-SMA expression.
Discussion
Although it is now well accepted that TGF-beta/Smad signaling
is a major pathway leading to end-stage liver failure featuring with
cirrhosis, treatments for hepatic fibrosis remain non-specific and
ineffective. In this study, we reported here that AA, a natural
product from Centella asiatica, may be a novel therapeutic agent for
liver fibrosis. Administration of AA significantly inhibited CCl4-
induced activation of HSC and liver fibrosis and largely improved
liver functional injury in a dosage-dependent manner in rats. In
addition, we also found that addition of AA was able to block
TGF-beta1-induced HSC activation such as a-SMA+ myofibro-
blast transition and collagen matrix expression in a rat HSC-T6
cell line. More importantly, upregulation of hepatic Smad7,
thereby blocking TGF-beta/Smad signaling, may be the under-
lying mechanism by which AA attenuated CCl4-induced liver
Figure 10. Knockdown of Smad7 from HSC-T6 cells prevents the
inhibitory effect of AA on TGF-beta1-induced hepatic fibrosis in
vitro.A .Real-time PCR shows reduction of Smad7 mRNA by siRNA
technique. B. Western blot analysis detects that knockdown of Smad7
from HSC-T6 cells results in a loss of AA (20 uM)-induced inhibition of
TGF-beta1 (1 ng/ml)-mediated collagen I and a-SMA expression at 24 h.
Data represent mean 6 SEM for at least 3 independent experiments.
*p,0.05, **p,0.01, ***p,0.001 versus control;
###p,0.001 versus TGF-
beta1, DMSO, and control vector (P-super)-treated cells.
doi:10.1371/journal.pone.0031350.g010
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ECM production in vitro.
In the context of liver fibrosis, TGF-beta1 is a key mediator to
activate HSCs to transform into a-SMA+ myofibroblast-like cells,
a cell type producing ECM during fibrogenesis [2–5]. It has been
shown that AA derivatives are able to inhibit ECM production by
HSC and keloid fibroblasts by blocking the autocrine effect of
TGF-beta1 in vitro [32,33]. The present study added new
information that AA was capable of blocking exogenous TGF-
beta1-induced myofibroblast transition and collagen I matrix
expression by HSC, suggesting that AA may counter-regulate the
profibrotic effect of TGF-beta1 in liver fibrosis. This was further
confirmed in vivo in a rat model of CCl4-induced hepatic fibrosis in
which treatment with AA significantly attenuated CCl4-induced
liver fibrosis and functional injury. All these findings demonstrated
that AA may be a novel and effective therapeutic agent for
hepatofibrosis.
A novel and significant finding in the present study was the
identification that AA-induced upregulation of hepatic Smad7,
thereby inhibiting TGF-beta/Smad signaling, was a mechanism
by which AA inhibits CCl4 or TGF-beta1-induced HSC activation
and liver fibrosis in vivo and in vitro. Indeed, activation of TGF-
beta/Smad signaling is a key mechanism of liver fibrosis in both
experimental and human chronic liver diseases [2–4]. The
functional importance of TGF-beta/Smad signaling in liver
fibrosis has been demonstrated by the finding that disruption of
Smad3 protects against dimethylnitrosamine-induced hepatic
fibrosis [8]. In contrast, deletion of Smad7, an inhibitor of TGF-
beta/Smad signaling, enhances CCl4-induced liver damage and
fibrosis in mice [9]. In the present study, CCl4-induced liver
fibrosis was associated with a marked activation of Smad2/3 but a
loss of Smad7, suggesting that the imbalance between Smad2/3
and Smad7 signaling could be important in the pathogenesis of
liver fibrosis. This is confirmed by the recent studies that
overexpression of Smad7 in the liver attenuates TGF-beta/Smad
signaling and protects against HSC activation and liver fibrogen-
esis in CCl4-induced mouse and rat models [10,11]. Although the
mechanisms of TGF-beta/Smad-mediated liver fibrosis are well
understood, the development of therapeutic drugs directly
targeting this pathway remains unexplored. The present study
identified that treatment with AA was able to induce hepatic
Smad7, thereby blocking TGF-beta/Smad signaling and fibrosis
in a rat model of CCl4-induced liver fibrosis and in TGF-beta1-
activated HSC in vitro. These results suggest that induction of
Smad7, thereby restoring the balance of TGF-beta/Smad
signaling, may be a central mechanism by which AA inhibits
liver fibrosis in vivo and in vitro. This was supported by the finding
that knockdown of Smad7 was able to protect against HSC from
TGF-beta1-induced activation and fibrosis in vitro.
In summary, the present study demonstrates that AA may be a
novel therapeutic agent for liver fibrosis. Induction of hepatic
Smad7, thereby inhibiting activation of TGF-beta/Smad signal-
ing, may be an underlying mechanism by which AA protects
against chronic liver disease associated with fibrosis.
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